Latest @ CSI.

View All
October 24, 2024
CSI Singapore Recognised in World’s Top 2% Most-Cited Scientists in 2024
CSI Singapore has been recognised in 'World’s Top 2% Most-Cited Scientists in 2024' in the latest update by Elsevier. Congratulations to Prof. Ashok and Dr. Tony for their commendable efforts...
Read More »
October 3, 2024
Recipients of The Distinguished Senior Clinician Award (DSCA), Prof Chng Wee Joo and Prof. Lee Soo Chin
Warmest congratulations to CSI Senior Principal Investigators, Prof. Chng Wee Joo and Prof. Lee Soo Chin for being awarded, The Distinguished Senior Clinician Award (DSCA). The Ministry of Health grants...
Read More »

Press Release

View All
Pembrolizumab With or Without Bevacizumab in Platinum-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Randomized, Open-Label, Phase 2 Trial (The Lancet Oncology, Feb 2025)

Wan-Qin Chong, MBBS a ∙ Jia-Li Low, MBBS a ∙ Joshua K Tay, PhD b,d ∙ Thi Bich Uyen Le, BSca ∙ Grace Shi-Qing Goh, BSc g ∙ Kenneth Sooi, MBBS a ∙ Hui-Lin Teo, MBBS h ∙ Seng-Wee Cheo, MD a ∙ Regina Tong-Xin Wong, BSc g ∙ Jens Samol, MD h,j,k ∙ Ming-Yann Lim, MBBS i ∙ Hao Li, MBBS i ∙ Niranjan Shirgaonkar, MSc l ∙ Shumei Chia, PhD l ∙ Lingzhi Wang, PhD f,g ∙ Anil Gopinathan, MBBS c ∙ Donovan Kum-Chuen Eu, MBBS b ∙ Raymond King-Yin Tsang, MBChB b,d ∙ Prof Kwok-Seng Loh, MBBS b,d ∙ Prof Han-Chong Toh, MBBS m ∙ Nicholas Syn, MBBSe ∙ Li-Ren Kong, PhD f,g ∙ Ramanuj Dasgupta, PhD l ∙ Bee-Choo Tai, PhD n ∙ Yaw-Chyn Lim, PhD …

Pembrolizumab With or Without Bevacizumab in Platinum-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Randomized, Open-Label, Phase 2 Trial (The Lancet Oncology, Feb 2025) Read More »

Follow Us on Twitter

Upcoming Events

View All
×

CSI Web Experience Survey Form

Please Rate Your Satisfaction

Overall Satisfaction For This Site:
Visual Appeal:
Ease Of Finding Information:
Relevance Of Information:
Readability Of Information:
Did you accomplish what you wanted to do today on this site?